In 2004 Paul Batchedler and Dena Raley, colleagues at a large health care company, pooled a few thousand dollars and started Clinimark. From a small initial laboratory, they continued to refine their process and approach, eventually building the business into a leading expert in pulse oximetry and both invasive and non-invasive blood pressure.

While political pundits might consider 2013 the year of the “no,” biotechies might think about it as the year of the “know.”  Who can know what, what knowledge is patentable, and knowing how it can be used were all issues which found a newly devoted audience, including seven people in long robes…

23andMe is a high-profile startup that offers direct-to-consumer DNA testing.  Send in a little spit swab, and they provide a variety of contextual reports on inherited traits, genealogy, and possible congenital risks. Their home test – most recently priced at just $99 — received notice within Time’s Best Inventions of 2008…

In 2006, after a sudden shift in the outcomes of a promising drug, Pfizer’s market cap plummeted by $21 billion in a week.  Stories like this are common in the pharmaceutical industry, only this one was different…